Takeda Pharmaceutical Company Ltd
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
A Study of Soticlestat in Healthy Adults To Evaluate the Effect on QTc Interval
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Takeda
- Registration Number
- NCT05309902
A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)
- Conditions
- Coronavirus Disease (COVID-19)
- Interventions
- Biological: TAK-019
- First Posted Date
- 2022-03-29
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 150
- Registration Number
- NCT05299359
- Locations
- 🇯🇵
PS Clinic, Fukuoka, Japan
🇯🇵Sumida Hospital, Sumida-ku, Tokyo, Japan
A Study of Chinese Adults With Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 934
- Registration Number
- NCT05288491
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
🇨🇳Shanxi Cancer Hospital, Taiyuan, Shanxi, China
🇨🇳Tongji Medical College of Hust, Wuhan, Hubei, China
A Study of Soticlestat Tablets in Healthy Adults
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 96
- Registration Number
- NCT05284760
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study to Assess the Hypersensitivity to TAK-880 Compared to Gammagard S/D in Blood of Children, Teenagers and Adults
- Conditions
- Drug Hypersensitivity
- Interventions
- Other: No intervention
- First Posted Date
- 2022-03-07
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Takeda
- Target Recruit Count
- 72
- Registration Number
- NCT05269082
- Locations
- 🇺🇸
PPD, Wilmington, North Carolina, United States
A Study on Estimated Risks of Certain Adverse Events in Adults With Von Willebrand Disease (VWD) Treated With Veyvondi
- Conditions
- Von Willebrand Disease (VWD)
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Takeda
- Target Recruit Count
- 102
- Registration Number
- NCT05265078
- Locations
- 🇩🇪
MVZ Gerinnungszentrum Hochtaunus, Bad Homburg vor der Höhe, Hessen, Germany
First-in-Human Study of TAK-280 in Participants With Solid Tumors
- Conditions
- Unresectable Locally Advanced or Metastatic Cancer
- Interventions
- Drug: TAK-280
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Takeda
- Target Recruit Count
- 182
- Registration Number
- NCT05220098
- Locations
- 🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States
🇺🇸University of Arkansas For Medical Sciences, Little Rock, Arkansas, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
A Chart Review Study of Adults With Advanced NSCLC
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 179
- Registration Number
- NCT05207423
- Locations
- 🇫🇷
CHU Strasbourg - Nouvel Hopital Civil, Strasbourg, Rhone, France
🇨🇦University Health Network Princess Margaret Cancer Research Tower (PMCRT) The MaRS Centre, East Tower, Toronto, Ontario, Canada
🇫🇷Centre Hospitalier de Saint-Quentin, Saint-Quentin cedex, Aisne, France
A Study of Vedolizumab in Adults With Crohn's Disease (CD)
- Conditions
- Crohn's Disease
- Interventions
- Other: No Intervention
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 72
- Registration Number
- NCT05192863
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
🇮🇱Sheba Medical Center, Ramat Gan, Israel
🇮🇹ASST Fatebenefratelli Sacco, Milano, Italy
A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- Takeda
- Registration Number
- NCT05183139